ストックスクリーナーアプリを入手
7.16
2.07%
0.145
Mind Medicine Inc (MNMD) 最新ニュース
Chardan Capital Initiates Coverage of Mind Medicine (MNMD) with Buy Recommendation - MSN
Mind Medicine (MindMed) (NASDAQ:MNMD) Now Covered by Analysts at Chardan Capital - MarketBeat
Wellington Management Group LLP Purchases 109,152 Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - MarketBeat
MindMed joins Nasdaq Biotechnology Index - Investing.com
MindMed Joins Nasdaq Biotech Index After Landmark Year of $250M Funding and Clinical Advances - StockTitan
Objective long/short (MNMD) Report - Stock Traders Daily
Mind Medicine (MindMed) (NASDAQ:MNMD) Trading 4.9% HigherStill a Buy? - MarketBeat
Mind Medicine (MindMed) (NASDAQ:MNMD) Receives "Outperform" Rating from Oppenheimer - MarketBeat
MindMed doses first subject in trial of tablets for generalised anxiety disorder - Yahoo Finance
MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD) - newsbreak.com
Brokerages Set Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Price Target at $27.71 - MarketBeat
Mind Medicine's SWOT analysis: stock poised for growth in anxiety treatment By Investing.com - Investing.com South Africa
Mind Medicine's SWOT analysis: stock poised for growth in anxiety treatment - Investing.com India
MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress - Business Wire
MindMed Showcases Breakthrough LSD Treatment Data for Anxiety Disorder at Major Congress - StockTitan
Learn to Evaluate (MNMD) using the Charts - Stock Traders Daily
MindMed awarded Innovation Passport for MM120 - The Pharma Letter
Insider Buying: David Gryska Acquires Additional Shares of Mind Medicine Inc (MNMD) - GuruFocus.com
Mind Medicine director David Gryska acquires $17,925 in shares - Investing.com
Mind Medicine director David Gryska acquires $17,925 in shares By Investing.com - Investing.com Nigeria
MindMed gains UK Innovation Passport for GAD treatment - Investing.com
MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD) - Business Wire
MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy - citybiz
MindMed appoints new VP of R&D Strategy - Investing.com
MindMed appoints new VP of R&D Strategy By Investing.com - Investing.com UK
MindMed Announces New Employee Inducement Grants - Business Wire
MindMed Issues Stock Options to New Employees in Latest Inducement Grant - StockTitan
Mind Medicine (MindMed) (NASDAQ:MNMD) Trading Down 3%Time to Sell? - MarketBeat
Ally Bridge Group NY LLC Decreases Stock Holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - MarketBeat
Mind Medicine (NEOE:MMED) Change In Inventory : C$0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
MindMed's SWOT analysis: psychedelic stock's potential in anxiety treatment - Investing.com
Roth Capital Issues Pessimistic Estimate for MNMD Earnings - MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives $25.38 Average Price Target from Brokerages - MarketBeat
Generalized Anxiety Disorder Market to Reach New Heights - openPR
MindMed recruits regulatory expert ahead of Phase III trials - The Pharma Letter
Vera hires Jason Carter as chief legal officer - BioCentury
MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer - BioSpace
MindMed Appoints Former Karuna Executive to Lead Phase 3 Regulatory Strategy | MNMD Stock News - StockTitan
(MNMD) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Is Mind Medicine (MNMD) the Best Multibagger Stock to Buy Heading into 2025? - Insider Monkey
Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Gap UpHere's What Happened - MarketBeat
Stock Traders Purchase Large Volume of Call Options on Mind Medicine (MindMed) (NASDAQ:MNMD) - MarketBeat
COMMODORE CAPITAL LP Acquires Shares in Mind Medicine Inc - GuruFocus.com
10 Best Multibagger Stocks To Buy Heading into 2025 - Insider Monkey
Mind Medicine (MindMed) Inc.'s (NASDAQ:MNMD) market cap touched US$601m last week, benefiting both retail investors who own 41% as well as institutions - Yahoo Finance
Mind Medicine Mindmed Inc (MNMD-Q) QuotePress Release - The Globe and Mail
Can Canada’s psychedelic drug developers shake off the sector’s bad trip? - The Globe and Mail
MindMed to Participate in Upcoming Investor Conferences - Business Wire
Mind Medicine (MindMed)'s (MNMD) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Mind Medicine: No News = Good News (NASDAQ:MNMD) - Seeking Alpha
Adam Stanecki on Mind Medicine with Charles Kovess11 November 2023 - imdb
MindMed Advances Phase 3 Trials in Mental Health - TipRanks
Mind Medicine Inc (MNMD) Q3 2024 Earnings Call Highlights: Strong Cash Position and Clinical ... By GuruFocus - Investing.com Canada
Mind Medicine Inc (MNMD) Q3 2024 Earnings Call Highlights: Stron - GuruFocus.com
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):